Cleaved-CTSV (L114) Antibody

What is the Cleaved-CTSV (L114) Antibody and what epitope does it target?

Cleaved-CTSV (L114) Antibody (product code CSB-PA000037) is a polyclonal antibody that specifically recognizes the internal region of human Cathepsin L2 (CTSV). This antibody was developed using a synthesized peptide derived from the internal region of Human Cathepsin L2 as the immunogen. The antibody targets the CTSV protein (UniProt ID: O60911), also known as Cathepsin L2, Cathepsin U, or Cathepsin V, with specific recognition of the cleaved form at Leucine 114 . The antibody's specificity allows researchers to distinguish between intact and cleaved forms of the protease, which may have different functional implications in various biological processes, particularly in the context of proteolytic activity studies in disease models .

What species reactivity does the Cleaved-CTSV (L114) Antibody demonstrate?

The Cleaved-CTSV (L114) Antibody has been validated to react with human and monkey samples . Some variants of CTSV antibodies may also demonstrate reactivity with mouse and rat samples, though this appears to be product-specific . When planning cross-species experiments, researchers should verify reactivity through preliminary validation studies, as sequence homology between species may affect antibody performance. Western blot analysis with positive control samples from each species of interest is recommended to confirm cross-reactivity before proceeding with comprehensive experimental designs .

Which experimental applications is the Cleaved-CTSV (L114) Antibody validated for?

The Cleaved-CTSV (L114) Antibody has been specifically validated for Western Blot (WB) and ELISA applications, with recommended dilutions of 1:500-1:2000 for WB and 1:20000 for ELISA . Western blot validation has been confirmed using HeLa cells, demonstrating specific detection of cleaved Cathepsin L2 at the L114 position . The antibody's high specificity makes it particularly valuable for distinguishing between intact and cleaved forms of CTSV in experimental settings where proteolytic processing may have functional significance. While not explicitly validated for other applications, researchers might consider optimization for immunohistochemistry or immunofluorescence, though additional validation would be necessary .

What are the optimal storage conditions for maintaining Cleaved-CTSV (L114) Antibody activity?

The Cleaved-CTSV (L114) Antibody should be stored at -20°C or -80°C immediately upon receipt to maintain optimal reactivity and specificity . The product is provided in liquid form in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide, which helps stabilize the antibody during storage . Researchers should avoid repeated freeze-thaw cycles as these can compromise antibody performance through denaturation and aggregation . For working solutions, aliquoting the stock antibody into smaller volumes before freezing is strongly recommended to minimize freeze-thaw cycles. When briefly handling the antibody during experimentation, keeping it on ice and returning it to appropriate storage promptly will help preserve its reactivity over time .

How should Western Blot protocols be optimized for Cleaved-CTSV (L114) Antibody?

For optimal Western Blot results with Cleaved-CTSV (L114) Antibody, researchers should implement the following protocol optimizations:

• Sample preparation: Extract proteins using lysis buffers containing protease inhibitors to prevent artificial proteolysis during processing.

• Dilution optimization: Start with a 1:1000 dilution in 5% BSA or milk in TBST, then adjust based on signal intensity and background levels .

• Incubation conditions: Primary antibody incubation should be performed overnight at 4°C to maximize specific binding while minimizing background.

• Detection systems: HRP-conjugated secondary antibodies at 1:5000-1:10000 dilutions are recommended, with both chemiluminescent and fluorescent detection systems being suitable.

• Positive controls: Include HeLa cell lysates as positive controls, as these have been validated for detecting cleaved CTSV .

• Blocking optimization: 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature is typically sufficient, though BSA may be preferred for phospho-specific applications.

This methodological approach ensures reliable detection of cleaved CTSV while minimizing non-specific binding and optimizing signal-to-noise ratios .

What considerations are important for ELISA applications with this antibody?

For ELISA applications with Cleaved-CTSV (L114) Antibody, several methodological considerations are critical:

• Antibody dilution: The recommended dilution for ELISA is 1:20000, which is significantly more dilute than for Western blot applications, reflecting the higher sensitivity of ELISA methods .

• Blocking optimization: 1-5% BSA in PBS is often suitable for blocking, with overnight incubation at 4°C for the capture antibody coating step.

• Sample preparation: Cell lysates or biological fluids should be cleared by centrifugation and filtered if necessary to remove particulates that might interfere with binding.

• Standard curve generation: Recombinant CTSV protein can be used to generate a standard curve, allowing for quantitative measurement.

• Signal development: TMB substrate with stopping solution provides a colorimetric readout that can be measured at 450nm, with development times typically optimized between 5-30 minutes.

• Cross-validation: Results should be cross-validated with Western blot analysis to confirm specificity, particularly when working with complex biological samples.

These methodological details enhance assay reproducibility and data reliability when using this antibody for ELISA applications .

How can the Cleaved-CTSV (L114) Antibody be used to study proteolytic processing in disease models?

The Cleaved-CTSV (L114) Antibody offers a sophisticated approach to investigating proteolytic processing in various disease models, particularly those involving inflammatory and tumor microenvironments. Researchers can implement the following methodological strategies:

• Comparative analysis: Analyze cleaved versus total CTSV levels across normal and diseased tissues to determine processing dynamics. This requires parallel detection with antibodies recognizing total CTSV and the cleaved form specifically.

• Cell-type specific processing: Use immunofluorescence co-staining with cell-type markers to identify which cells within heterogeneous tissues exhibit CTSV cleavage.

• Protease inhibitor studies: Employ selective protease inhibitors to identify which proteases mediate CTSV cleavage in specific disease contexts, potentially revealing therapeutic targets.

• Time-course experiments: Monitor CTSV cleavage during disease progression to establish temporal relationships between proteolytic processing and disease severity.

• Correlation with functional outcomes: Relate cleaved CTSV levels to functional parameters such as cell invasion, migration, or matrix degradation to establish causal relationships.

This antibody provides a valuable tool for dissecting the roles of protease networks in disease pathogenesis, as proteases capable of cleaving CTSV are found within inflammatory and tumor microenvironments .

What is the relationship between Cathepsin V cleavage and anti-hinge antibody (AHA) recognition in cancer immunotherapy?

The relationship between Cathepsin V cleavage and anti-hinge antibody (AHA) recognition represents an emerging area of research with implications for cancer immunotherapy efficacy. The methodological approach to studying this relationship involves:

• In vitro cleavage assays: Therapeutic antibodies can be subjected to controlled proteolytic cleavage by Cathepsin V, generating F(ab')₂ fragments that retain antigen binding but lack Fc-mediated effector functions .

• AHA binding studies: Anti-hinge antibodies specifically recognize epitopes exposed following proteolytic cleavage in the hinge region, rather than intact IgG. This recognition can be quantified using ELISA or surface plasmon resonance .

• Functional consequence analysis: Following AHA binding to cleaved therapeutic antibodies, researchers can assess functional restoration of effector activities such as complement-dependent cytotoxicity (CDC) .

• Patient sample correlation: AHA levels in patient serum samples can be correlated with treatment outcomes for patients receiving antibody-based immunotherapies to determine clinical relevance.

Research suggests that proteases within tumor microenvironments may cleave therapeutic antibodies like anti-PD-1 treatments, potentially modulating their efficacy. AHA recognition of these cleaved fragments may partially restore effector functions, representing a previously unrecognized factor influencing immunotherapy outcomes .

How does CTSV proteolytic activity differ across cancer types and what methodologies best capture these differences?

CTSV (Cathepsin V/L2) proteolytic activity exhibits distinct patterns across cancer types, requiring sophisticated methodological approaches for comprehensive characterization:

• Activity-based probes: Fluorescent activity-based probes specific for CTSV can be used to measure active enzyme levels in tissue samples, providing spatial information beyond mere protein expression.

• Substrate specificity profiling: Synthetic peptide libraries can be used to determine if CTSV from different cancer types displays altered substrate preferences, potentially reflecting disease-specific modifications.

• Proteomic identification of substrates: Comparative proteomics between control and CTSV-inhibited samples can identify cancer-specific substrates, revealing context-dependent functions.

• Multiplex analysis of cathepsin networks: Given functional redundancy among cathepsins, simultaneous assessment of multiple family members provides more comprehensive understanding than single-target approaches.

• Live-cell imaging: Real-time visualization of CTSV activity using FRET-based reporters allows dynamic assessment of proteolytic activity in response to microenvironmental changes.

These methodological approaches can reveal how CTSV activity contributes to processes like extracellular matrix degradation, cell invasion, and immune evasion across cancer types . Research indicates that CTSV dysregulation is observed in various cancers, cardiovascular diseases, and autoimmune disorders, making it a promising target for therapeutic interventions .

What are common challenges in detecting cleaved forms of CTSV and how can they be addressed?

Detecting cleaved forms of CTSV presents several methodological challenges that researchers should anticipate and address:

• Artificial proteolysis during sample preparation: This can be mitigated by including multiple protease inhibitors in lysis buffers and maintaining samples at 4°C throughout processing. Rapid sample processing and the addition of specific cysteine protease inhibitors like E-64 are particularly important .

• Distinguishing specific cleavage events: The L114 cleavage site represents a specific proteolytic event, but other cleavage products may be present. Comparing results with antibodies recognizing different epitopes can help identify specific processing events .

• Low abundance of cleaved forms: Enrichment strategies such as immunoprecipitation before Western blot analysis can enhance detection of low-abundance cleaved forms.

• Cross-reactivity with related cathepsins: Validation using CTSV-knockout or knockdown samples is essential to confirm specificity, as cathepsin family members share significant sequence homology.

• Rapid degradation of cleaved products: Pulse-chase experiments can help capture transient cleaved forms that may be rapidly degraded in cellular systems.

• Variability in cleavage across cell types: Systematic screening across multiple cell lines or primary cells is recommended to identify optimal model systems for studying CTSV cleavage .

These methodological approaches help ensure that observed signals truly represent the cleaved form of CTSV at the L114 position rather than artifacts or related proteases.

How can researchers differentiate between specific and non-specific signals in Western blots using Cleaved-CTSV (L114) Antibody?

Differentiating between specific and non-specific signals when using Cleaved-CTSV (L114) Antibody requires rigorous methodological controls and analytical approaches:

• Molecular weight verification: Cleaved CTSV at L114 should appear at a predictable molecular weight based on the cleavage site location. This should be compared with theoretical predictions and literature reports.

• Validation with knockdown/knockout controls: siRNA knockdown or CRISPR knockout of CTSV should eliminate specific bands while leaving non-specific signals unchanged.

• Peptide competition assays: Pre-incubation of the antibody with the immunizing peptide should abolish specific signals while non-specific binding typically remains.

• Positive control samples: Include HeLa cell lysates as positive controls, as these have been validated for detecting cleaved CTSV .

• Gradient gel analysis: Using gradient gels can help resolve closely migrating bands that might otherwise be confounded.

• Comparison with total CTSV antibody: Parallel blots using antibodies against total CTSV can help confirm identity of cleaved forms.

• Recombinant protein standards: Including recombinant CTSV protein (both full-length and cleaved forms if available) provides definitive molecular weight references.

These methodological controls help ensure experimental rigor and data reliability when interpreting Western blot results with this antibody .

What controls and validation steps are essential when studying CTSV cleavage in complex biological samples?

When studying CTSV cleavage in complex biological samples such as tissue homogenates, serum, or tumor specimens, several critical methodological controls and validation steps are essential:

• Sample-matched intact tissue controls: Comparing flash-frozen samples with those subjected to various processing delays can reveal artificial cleavage events.

• Protease inhibitor panels: Systematic testing with selective inhibitors can identify which proteases mediate CTSV cleavage in specific sample types.

• Multiple antibody verification: Using antibodies recognizing different epitopes on CTSV helps confirm the identity of observed bands and cleavage patterns.

• Mass spectrometry validation: MS/MS analysis of immunoprecipitated proteins can provide definitive identification of cleavage sites and confirm antibody specificity.

• Recombinant enzyme digestion: In vitro digestion of recombinant CTSV with relevant proteases creates reference standards for cleavage products.

• Species cross-reactivity verification: When working with animal models, antibody specificity should be validated for each species due to potential sequence variations at the epitope.

• Purified F(ab')₂ controls: In studies involving antibody cleavage, inclusion of purified F(ab')₂ fragments provides positive controls for recognition patterns .

These methodological controls help distinguish genuine biological cleavage events from artifacts, particularly important when studying proteolytic processing in complex disease microenvironments .

What is the biological significance of CTSV cleavage in cancer progression and potential therapeutic interventions?

The cleaved form of Cathepsin V (CTSV) has significant biological implications in cancer progression through several mechanistic pathways:

• Extracellular matrix remodeling: Cleaved CTSV demonstrates altered substrate specificity compared to intact CTSV, potentially enhancing degradation of specific ECM components that facilitate tumor invasion and metastasis.

• Growth factor processing: CTSV cleavage can modify its ability to process growth factors and cytokines, influencing autocrine and paracrine signaling within the tumor microenvironment.

• Therapeutic antibody modulation: In cancer immunotherapy contexts, proteases including cathepsins can cleave therapeutic antibodies, potentially altering their efficacy. Anti-hinge antibodies (AHA) that recognize these cleaved forms may partially restore function, representing a complex interplay affecting treatment outcomes .

• Biomarker potential: Elevated levels of cleaved CTSV have been associated with poor outcomes in certain cancers, similar to findings with cleaved IgG in breast cancer .

• Protease network interactions: CTSV cleavage represents one node in complex protease networks within tumor microenvironments, where cascade activation can amplify proteolytic activity.

Understanding CTSV cleavage has therapeutic implications, including the development of selective inhibitors targeting specific cathepsin family members or their activation pathways, as well as the design of protease-resistant therapeutic antibodies for immunotherapy applications .

How does CTSV cleavage relate to other cathepsin family members in protease networks during disease pathogenesis?

CTSV (Cathepsin V/L2) cleavage occurs within complex protease networks where multiple cathepsin family members interact functionally during disease pathogenesis:

• Hierarchical activation cascades: CTSV may be activated by other proteases, including other cathepsins, in sequential activation cascades that amplify proteolytic activity. Similarly, cleaved CTSV may activate other downstream proteases.

• Substrate competition and complementation: CTSV shares substrate preferences with other cathepsins (particularly Cathepsin L), but cleavage can modify these preferences, creating unique activity profiles relevant to disease progression.

• Compensatory mechanisms: In experimental systems where one cathepsin is inhibited, others often demonstrate compensatory upregulation, highlighting the importance of studying the entire protease network rather than individual members in isolation.

• Compartment-specific activities: Unlike some cathepsins that function primarily in lysosomes, CTSV demonstrates significant activity in other cellular compartments and the extracellular space, particularly after specific cleavage events that may stabilize the enzyme outside its canonical environment.

• Disease-specific protease signatures: Different diseases exhibit characteristic patterns of cathepsin expression and activation, with specific cleavage events potentially serving as biomarkers or therapeutic targets.

Research indicates that cleaved forms of cathepsins, including CTSV, may have altered half-lives, substrate preferences, and inhibitor susceptibilities compared to their intact counterparts, making them functionally distinct entities in disease processes .

What implications does anti-hinge antibody (AHA) recognition of cleaved proteins have for immunotherapy research?

The recognition of cleaved proteins by anti-hinge antibodies (AHA) has significant methodological and conceptual implications for immunotherapy research:

• Modulation of therapeutic antibody function: When therapeutic antibodies undergo proteolytic cleavage in tumor or inflammatory microenvironments, they retain antigen binding capacity but lose Fc-mediated effector functions. AHA recognition of these cleaved fragments may partially restore these functions, representing a previously unrecognized factor in treatment efficacy .

• Patient stratification potential: Levels of circulating AHA vary between individuals and may affect responses to antibody-based immunotherapies. Methodology for measuring AHA levels could enable patient stratification for optimal treatment selection .

• Biomarker development: The presence of cleaved antibody fragments in circulation or tissues may serve as biomarkers for protease activity within disease microenvironments.

• Novel combination approaches: Understanding the interplay between proteases, therapeutic antibodies, and AHA opens possibilities for combination therapies that protect antibodies from cleavage or enhance AHA-mediated functional rescue.

• Therapeutic antibody engineering: Knowledge of cleavage susceptibility enables the design of cleavage-resistant antibodies through strategic mutations or modifications to the hinge region.